Adrenomedullin optimises mortality prediction in COPD patients

Area of Science:

• Pulmonary Medicine
• Biomarkers
• Prognostic Modeling

Background:

• Existing COPD mortality scores may not fully capture systemic disease components.
• The role of circulating proadrenomedullin (MR-proADM) in COPD prognosis requires further evaluation.

Purpose of the Study:

• To assess the predictive accuracy of MR-proADM alone and in combination with established indices (ADO, updated ADO, BOD) for all-cause mortality in stable COPD patients.

Main Methods:

• Pooled data analysis of 1285 patients from the COMIC and PROMISE-COPD studies.
• Evaluation of MR-proADM levels and its combination with ADO, updated ADO, and BOD indices.
• Utilized C-statistic and net reclassification improvement (NRI) to assess predictive accuracy.

Main Results:

• Higher MR-proADM levels (≥0.87 nmol/l) were associated with a 2.1-fold increased mortality risk (p < 0.001).
• The ADOA index (ADO + MR-proADM) demonstrated the highest predictive accuracy (C=0.72), followed by BODA (BOD + MR-proADM) (C=0.71).
• Incorporating MR-proADM significantly improved the prediction of 1- and 2-year mortality, with substantial reclassification improvements.

Conclusions:

• MR-proADM significantly enhances the prognostic capabilities of the BOD, ADO, and updated ADO indices.
• The combination of MR-proADM with existing scores offers a more accurate prediction of mortality in stable COPD.